Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
NCT04856124 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2021-04-23
Summary
This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for treatment-resistant depression.
Conditions
Interventions
- DRUG
-
Intranasal esketamine
Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
Sponsors & Collaborators
-
Psych Atlanta
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-01
- Primary Completion
- 2020-12-15
- Completion
- 2021-03-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
NCT02782104 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
NCT03185819 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
NCT02422186 ·Status: COMPLETED ·Phase: PHASE3
-
Intranasal Ketamine in Treatment-Resistant Depression
NCT01304147 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
NCT01998958 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
NCT02497287 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
NCT04829318 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
NCT03852160 ·Status: WITHDRAWN ·Phase: PHASE3
-
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
NCT07146503 ·Status: RECRUITING
-
Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI
NCT05320120 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
NCT01640080 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
NCT02918318 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
NCT02493868 ·Status: COMPLETED ·Phase: PHASE3
-
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
NCT01582945 ·Status: COMPLETED ·Phase: NA
-
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
NCT03039192 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
NCT02610712 ·Status: UNKNOWN ·Phase: PHASE4
-
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
NCT03097133 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ketamine in Patients With Treatment-resistant Depression
NCT01627782 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
NCT04338321 ·Status: COMPLETED ·Phase: PHASE3
-
Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression
NCT04234776 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454 ·Status: RECRUITING ·Phase: PHASE3
-
A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants
NCT02129088 ·Status: COMPLETED ·Phase: PHASE1
-
Ketamine for Treatment Resistant MDD
NCT04021433 ·Status: UNKNOWN ·Phase: NA
-
Intra-nasal vs. Intra-venous Ketamine Administration
NCT02644629 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
NCT04216888 ·Status: COMPLETED ·Phase: PHASE2/PHASE3